Patent ductus arteriosus medical therapy
|
Patent Ductus Arteriosus Microchapters |
|
Differentiating Patent Ductus Arteriosus from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Medical Therapy |
|
Case Studies |
|
Patent ductus arteriosus medical therapy On the Web |
|
American Roentgen Ray Society Images of Patent ductus arteriosus medical therapy |
|
Risk calculators and risk factors for Patent ductus arteriosus medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Associate Editor-In-Chief:Cafer Zorkun, M.D., Ph.D. [2]; Keri Shafer, M.D. [3] Priyamvada Singh, MBBS [[4]]
Assistant Editor-In-Chief: Kristin Feeney, B.S. [[5]]
Medical Therapy
Infants without adverse symptoms may simply be monitored as outpatients, while symptomatic PDA can be treated with both surgical and non-surgical methods.[1] Medical therapy involves being treated with indomethacin (0,2mg/Kg IV) to close the PDA. Indomethacin therapy has known limitations in severe cases of PDA. Patients with cases involving the transposition of the great vessels (TGV) may need the ductus arteriosus kept open with prostaglandin E1 (PGE1). Often, these pateints require surgical intervention instead.
Fluid restriction and prostaglandin inhibitors such as indomethacin have also been used in successful non-surgical closure of the DA. This is an especially viable alternative for premature infants. If indomethacin fails or if a child is more than 6 to 8 months old, surgical ligation of the PDA can be accomplished with excellents results in uncomplicated patients. Recent experience with transcatheter closure has also been favorable, being today the procedure of choice for most patients.
References
- ↑ Zahaka, KG and Patel, CR. "Congenital defects.'" Fanaroff, AA and Martin, RJ (eds.). Neonatal-perinatal medicine: Diseases of the fetus and infant. 7th ed. (2002):1120-1139. St. Louis: Mosby.